BGLAP and Osteopenia: However, disregulated levels or pharmacological GC use promotes osteopenia and has multiple effects on osteoblasts including decreased proliferation, increased apoptosis, lowered osteoprotegerin (OPN), IL-6, IL-8, and osteocalcin (OCN) expression and elevated 11βhydroxysteroid dehydrogenase-1 (11βHSD-1) expression, among others [8].